An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
Primary:
To determine the recommended dose (RD) of BB-1701 for Dose Expansion
To assess the safety and tolerability of BB-1701 in each dose cohort
Secondary:
To assess additional efficacy measures of BB-1701 in each dose cohort
To characterize the pharmacokinetics
(PK) of BB-1701 and the relationship between BB-1701 exposure and selected efficacy and safety measures
- Rutgers Cancer Institute of New Jersey
Inclusion Criteria
- Male or female, aged >=18 years at the time of informed consent.
- Metastatic or unresectable BC that is histologically confirmed to be either
HER2-positive (defined as an immunohistochemistry [IHC] status of 3+, or a positive
in situ hybridization [ISH] test [fluorescence, chromogenic, or silver-enhanced ISH]
if IHC status is 2+) or HER2-low (defined as an IHC status of 1+, or 2+ and negative
ISH) per the American Society of Clinical Oncology/College of American Pathology
guidelines as documented prior to trastuzumab deruxtecan (T-DXd) treatment.
- Must have previously received T-DXd.
- Sufficient tumor tissue is required for HER2 status testing at a central laboratory.
- Measurable disease per RECIST 1.1 as assessed by the investigator. Participants with
bone only disease may be eligible if there is a measurable soft tissue component
associated with the bone lesion.
- Must have previously received at least 1 but no more than 3 prior chemotherapy-based
regimes in the unresectable or metastatic setting. If recurrence occurred during or
within 6 months of (neo) adjuvant chemotherapy, this would count as 1 line of
chemotherapy.
- If HR-positive HER2-low BC, must have previously received endocrine therapy and is
not expected to further benefit from it.
- ECOG PS 0 or 1.
- Life expectancy of at least 3 months.
- Adequate organ function and laboratory parameters.
Exclusion Criteria
- Presence of brain or subdural metastases, unless participant has completed local
therapy and has discontinued the use of corticosteroids for this indication for at
least 2 weeks prior to starting treatment in this study.
- Diagnosed with meningeal carcinomatosis.
- Received anticancer therapy (chemotherapy or other systemic anticancer therapies,
immunotherapy, radiation therapy, etc) or an investigational drug or device within
the past 28 days or 5 half-lives, whichever is shorter.
- Prior treatment with eribulin.
- Any prior allergic reactions of Grade >=3 to monoclonal antibodies or
contraindication to the receipt of corticosteroids or any of the excipients
(investigators should refer to the prescribing information for the selected
corticosteroid).
- Residual toxic effects of prior therapies or surgical procedures that is Grade >=2
(except alopecia or anemia).
- Grade >=2 peripheral neuropathy or history of Grade >=3 peripheral neuropathy or
discontinued any prior treatment due to peripheral neuropathy.
- Active pneumonitis/interstitial lung disease (ILD) or any clinically significant
lung disease (example, chronic obstructive pulmonary disease), history of Grade >=2
pneumonitis/ILD, or received radiotherapy to lung fields within 12 months of Cycle 1
Day 1 of study treatment.
- Congestive heart failure greater than (>) New York Heart Association Class II or
left ventricular ejection fraction (LVEF) less than (<) 50 percent (%) measured by
multigated acquisition scan (MUGA) or echocardiogram.
- Has a corrected QT interval prolongation per Fridericia formula (QTcF) >470
millisecond (ms) (for both males and females) based on screening triplicate 12-lead
ECG.
- Concomitant active infection requiring systemic treatment, except:
- If known to be human immunodeficiency virus (HIV)-positive, must be on anti-HIV
therapy for at least 4 weeks and have a clusters of differentiation 4+ T-cell
(CD4+) count >=350 cells per microliter (cells/mcL) and an HIV viral load <400
copies per milliliter (copies/mL).
- If meets the criteria for anti-hepatitis B virus (HBV) therapy, must agree to
take anti-HBV therapy, if known to be HBV-positive as defined by positive
hepatitis B surface antigen or hepatitis B core antibody. HBV viral load must
be undetectable.
- If known to be hepatitis C virus (HCV)-positive must have completed curative
therapy for HCV. HCV viral load must be undetectable.
- Known history of active bacillus tuberculosis (TB).
- Any medical or other condition which, in the opinion of the investigator would
preclude the participant's participation in the clinical study.
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.